Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management
Mario Sznol, Michael A. Postow, Marianne Davies, et al.
Cancer Treatment Reviews (2017) Vol. 58, pp. 70-76
Open Access | Times Cited: 266

Showing 1-25 of 266 citing articles:

A review of cancer immunotherapy toxicity
Lucy Boyce Kennedy, April K.S. Salama
CA A Cancer Journal for Clinicians (2020) Vol. 70, Iss. 2, pp. 86-104
Open Access | Times Cited: 1097
Immune-related adverse events of checkpoint inhibitors
Manuel Ramos‐Casals, Julie R. Brahmer, Margaret K. Callahan, et al.
Nature Reviews Disease Primers (2020) Vol. 6, Iss. 1
Open Access | Times Cited: 1004
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, et al.
Journal of the National Comprehensive Cancer Network (2019) Vol. 17, Iss. 3, pp. 255-289
Open Access | Times Cited: 515
Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
Angeliki M. Stamatouli, Zoe Quandt, Ana Luisa Perdigoto, et al.
Diabetes (2018) Vol. 67, Iss. 8, pp. 1471-1480
Open Access | Times Cited: 488
Early B cell changes predict autoimmunity following combination immune checkpoint blockade
Rituparna Das, Noffar Bar, Michelle Ferreira, et al.
Journal of Clinical Investigation (2018) Vol. 128, Iss. 2, pp. 715-720
Open Access | Times Cited: 345
Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls
Eli P. Darnell, Meghan J. Mooradian, Erez N. Baruch, et al.
Current Oncology Reports (2020) Vol. 22, Iss. 4
Closed Access | Times Cited: 303
Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors
Juwhan Choi, Sung Yong Lee
Immune Network (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 212
Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review
Jeroen de Filette, Joeri J. Pen, Lore Decoster, et al.
European Journal of Endocrinology (2019) Vol. 181, Iss. 3, pp. 363-374
Open Access | Times Cited: 207
Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance
Marcus Couey, R. Bryan Bell, Ashish Patel, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 182
Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study
Tomoko Kobayashi, Shintaro Iwama, Yoshinori Yasuda, et al.
Journal of the Endocrine Society (2018) Vol. 2, Iss. 3, pp. 241-251
Open Access | Times Cited: 168
Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis
Leitao Sun, Leyin Zhang, Jieru Yu, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 167
Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment
Norah A. Alturki
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4301-4301
Open Access | Times Cited: 50
Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study
Hongnan Mo, Jing Huang, Jiachen Xu, et al.
British Journal of Cancer (2018) Vol. 119, Iss. 5, pp. 538-545
Open Access | Times Cited: 146
Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
Emma C. de Moel, Elisa A. Rozeman, Ellen Kapiteijn, et al.
Cancer Immunology Research (2018) Vol. 7, Iss. 1, pp. 6-11
Open Access | Times Cited: 140
Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system
Yinghong Zhai, Xiaofei Ye, Fangyuan Hu, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 138
French Endocrine Society Guidance on endocrine side effects of immunotherapy
Fréderic Castinetti, F. Albarel, F. Archambeaud, et al.
Endocrine Related Cancer (2018) Vol. 26, Iss. 2, pp. G1-G18
Open Access | Times Cited: 124
Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Brief Review
Glenn Myers
Current Oncology (2018) Vol. 25, Iss. 5, pp. 342-347
Open Access | Times Cited: 113
Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity
Chien-Chun Steven Pai, Donald M. Simons, Xiaoqing Lu, et al.
Journal of Clinical Investigation (2018) Vol. 129, Iss. 1, pp. 349-363
Open Access | Times Cited: 111
Checkpoint Inhibitor–Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes
Venessa Tsang, Rachel T. McGrath, Roderick Clifton‐Bligh, et al.
The Journal of Clinical Endocrinology & Metabolism (2019) Vol. 104, Iss. 11, pp. 5499-5506
Open Access | Times Cited: 110
Thyroid disorders induced by checkpoint inhibitors
Silvia Martina Ferrari, Poupak Fallahi, Fabio Galetta, et al.
Reviews in Endocrine and Metabolic Disorders (2018) Vol. 19, Iss. 4, pp. 325-333
Closed Access | Times Cited: 104
Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS
Huanhuan Ji, Xuewen Tang, Zhi Dong, et al.
Clinical Drug Investigation (2019) Vol. 39, Iss. 3, pp. 319-330
Closed Access | Times Cited: 99
Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review
Maria Stelmachowska‐Banaś, Izabella Czajka-Oraniec
Endocrine Connections (2020) Vol. 9, Iss. 10, pp. R207-R228
Open Access | Times Cited: 98
Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies
Silvia Martina Ferrari, Poupak Fallahi, Giusy Elia, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 10, pp. 2560-2560
Open Access | Times Cited: 91
MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis
F. Albarel, Fréderic Castinetti, Thierry Brue
European Journal of Endocrinology (2019) Vol. 181, Iss. 3, pp. R107-R118
Open Access | Times Cited: 82
Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm
Caroline Robert, Aurélien Marabelle, Hugo Herrscher, et al.
Nature Reviews Clinical Oncology (2020) Vol. 17, Iss. 11, pp. 707-715
Closed Access | Times Cited: 82
Page 1 - Next Page

Scroll to top